Cotización Centessa Pharmaceuticals - 0ACX

Discusiones en tiempo real e ideas comerciales: opere con confianza con nuestra poderosa plataforma.

Premium

Último Precio

Postura de Compra

0.00

Postura de Venta

0.00

Volume Operado de la Acción

166

0.00 Rango del Día 0.00

0.00 Rango de 52 semanas 0.00

Capitalización de Mercado [m]

Precio Anterior

0.00

Precio de Apertura

Hora

16.93

(O)

Última hora de negociación

Volumen financiero

Precio Promedio Ponderado

Volumen promedio (3 m)

Acciones en circulación

0.00

Rendimiento del Dividendo

Ratio Precio/Utilidad

0.00

Beneficio por acción (BPA)

turnover

6.85M

Beneficio neto

-151.09M

Sector

Coml Physical, Biologcl Resh

Industria

Coml Physical, Biologcl Resh

Sitio web

www.centessa.com

Sede

Cheshire, Gbr

Fundado

Centessa Pharmaceuticals Plc is listed in the Coml Physical, Biologcl Resh sector of the London Stock Exchange with ticker 0ACX. The last closing price for Centessa Pharmaceuticals was US$0. Over the last year, Centessa Pharmaceuticals shares have traded in a share price range of US$ 0.00 to US$ 0.00.

Centessa Pharmaceuticals currently has 0 shares in issue.

Centessa Pharmaceuticals Reports Financial Results for the Third Quarter of 2024 and Provides Business Update

Centessa Pharmaceuticals Reports Financial Results for the Third Quarter of 2024 and Provides Business Update Announced additional interim data...

Centessa Pharmaceuticals Announces Pricing of Upsized $225,000,000 Public Offering of American Depositary Shares

Centessa Pharmaceuticals Announces Pricing of Upsized $225,000,000 Public Offering of American Depositary Shares BOSTON and LONDON, Sept. 12...

Centessa Pharmaceuticals Announces $150,000,000 Proposed Public Offering of American Depositary Shares

Centessa Pharmaceuticals Announces $150,000,000 Proposed Public Offering of American Depositary Shares BOSTON and LONDON, Sept. 11, 2024 (GLOBE...

Centessa Announces Positive Interim Phase 1 Clinical Data with its Novel Orexin Receptor 2 (OX2R) Agonist, ORX750, in Acutely Sleep-Deprived Healthy Volunteers

Centessa Announces Positive Interim Phase 1 Clinical Data with its Novel Orexin Receptor 2 (OX2R) Agonist, ORX750, in Acutely Sleep-Deprived...

Centessa Pharmaceuticals Announces Late-Breaking Poster Presentation of Non-Human Primate Data for ORX142, a Novel Orexin Receptor 2 (OX2R) Agonist, at the 27th Congress of the European Sleep Research Society (Sleep Europe 2024)

Centessa Pharmaceuticals Announces Late-Breaking Poster Presentation of Non-Human Primate Data for ORX142, a Novel Orexin Receptor 2 (OX2R...

Centessa Pharmaceuticals Reports Financial Results and Business Highlights for the Second Quarter of 2024

Centessa Pharmaceuticals Reports Financial Results and Business Highlights for the Second Quarter of 2024 Company advancing pipeline of potential...

Período †	Variación(Ptos)	Variación %	Apertura	Precio Máximo	Precio Mínimo	Avg. Vol. diario	Precio Promedio Ponderado
1	0	0	0	0	0	0	0	DE
4	0	0	0	0	0	0	0	DE
12	0	0	0	0	0	0	0	DE
26	0	0	0	0	0	0	0	DE
52	0	0	0	0	0	0	0	DE
156	0	0	0	0	0	0	0	DE
260	0	0	0	0	0	0	0	DE

0ACX - Preguntas Frecuentes

¿Cuál es el precio actual de las acciones de Centessa Pharmaceuticals?

El precio actual de las acciones de Centessa Pharmaceuticals es US$ 0.00

¿Cuál es el rango de negociación de 1 año para el precio de las acciones de Centessa Pharmaceuticals?

Centessa Pharmaceuticals ha negociado en un rango de US$ 0.00 a US$ 0.00 durante el último año

¿Cuál es la moneda de reporte de Centessa Pharmaceuticals?

Centessa Pharmaceuticals presenta sus resultados financieros en USD

¿Cuál es el último ingresos anual de Centessa Pharmaceuticals?

El último ingresos anual de Centessa Pharmaceuticals es USD 6.85M

¿Cuál es el último beneficio anual de Centessa Pharmaceuticals?

El último beneficio anual de Centessa Pharmaceuticals es USD -151.09M

¿Cuál es la dirección registrada de Centessa Pharmaceuticals?

La dirección registrada de Centessa Pharmaceuticals es 3RD FLOOR, 1 ASHLEY ROAD, ALTRINCHAM, CHESHIRE, WA14 2DT

¿Cuál es la dirección del sitio web de Centessa Pharmaceuticals?

La dirección del sitio web de Centessa Pharmaceuticals es www.centessa.com

¿En qué sector industrial opera Centessa Pharmaceuticals?

Centessa Pharmaceuticals opera en el sector COML PHYSICAL, BIOLOGCL RESH

Volumen
% Mayores Alzas
% Mayores Bajas

Símbolo	Precio	Vol.
CPAICapai Plc	0.1175p (40.72%)	901.7M
XTRXtract Resources Plc	0.75p (36.36%)	9.04M
EUAEurasia Mining Plc	7.40p (32.14%)	38.22M
STBSecure Trust Bank Plc	540.00p (28.57%)	560.29k
HAYDHaydale Graphene Industries Plc	0.1325p (20.45%)	60.48M
ONCOncimmune Holdings Plc	1.15p (-27.67%)	662.94k
HRNHornby Plc	14.00p (-26.32%)	847.78k
THRUThruvision Group Plc	0.65p (-23.53%)	36.04M
DISDistil Plc	0.065p (-21.21%)	5.94M
SYMESupply@me Capital Plc	0.003p (-20.00%)	340.56M
UKOGUk Oil & Gas Plc	0.0105p (10.53%)	906.2M
CPAICapai Plc	0.1175p (40.72%)	901.7M
PREMPremier African Minerals Limited	0.01025p (-3.30%)	610.07M
ENETEthernity Networks Ltd	0.0625p (-7.41%)	484.96M
EMEEmpyrean Energy Plc	0.1225p (0.00%)	340.91M

snoopycomic 7 minutos hace

Good luck

CLPT

biosectinvestor 9 minutos hace

Don't be ridiculous. We have a good idea what is charged, we have an idea of what the likely cost is going to be to patients and we know the contract is cost +15, but we can't know for now what the reimbursement is and we also know that this is a contractual relationship that is cancelable at will b

NWBO

MC10459 9 minutos hace

At lower and lower prices. . .

HMBL

USVIHI22 9 minutos hace

whoever sold this stock in the last 2 days needs to be under investigation for something.

IWAL

wdereb79 10 minutos hace

I mean … the man has been locked away from twitter for months. Clearly he has a lot to say. So, you never know. Nights early. Celebratory drinks. Then he gets that phone in his hand … BOOM. Lol

FNMA

USVIHI22 10 minutos hace

Next thing you know Jed's a millionaire and moved away from there.

IWAL

thecrusher2011 11 minutos hace

Lol you'll fall for anything won't you?

Snopes says this story is bogus. Two completely different alleged victim lawsuits filed had matching fake abandoned address and were traced to a guy who worked for the Jerry Springer show who had a track record of trolling the media.

MC10459 13 minutos hace

https://www.globenewswire.com/news-release/2025/03/13/3042265/0/en/Zeranovia-TM-Weight-Loss-Product-Shows-Promising-Results-in-Dosage-Trial.html

BDPT

wdereb79 13 minutos hace

Straight from the man’s fingertips seems like it would be more accurate to me, but what do I know.

FNMA

robinandthe7hoods 14 minutos hace

Few people understand the effect of presenting at the Roth Conference will have on Verses' stock price.
It will be massive...

VRSSF

my3sons87 16 minutos hace

Retribution shall belong to the longs. IDCC seems to be trading with the markets. Which at this time has no knowledge of what good things will soon be announced soon.

I think IDCC is holding up very well in this fiasco of a market due to the man made societal pervasive fiasco.

IDCC

Acme Investments 19 minutos hace

You are aware that the Govt you speak of is creating a Bitcoin Reserve?? Why are you here if you think Bitcoin is a pump and dump??

BTCUSD

boston745 20 minutos hace

I said this on Mar 9th but it is not the first time i suggested that this reverse merger plan, if it happens as i suspect, was in place since before Amedica became Sintx & NP Aerospace was divested.
If NP-Sintx RM, then watch for Zimmer Biomet to come out of the closet as well as other partne

arizona1 20 minutos hace

Your habitual sexual abuser president was convicted of rape by a jury of his peers. What's up with this?

https://uploads.disquscdn.com/images/0eb260e95386fecaaa522817c371cb15a32b91718c2a86e209b04f4991806c60.jpg?w=800&h=762

ron_66271 21 minutos hace

Please Note That The Signature Page is Blank.

PDF 8/8.

Background proof of the Derivative Market of the ISDA.

Ron

LEHNQ

manibiotech 21 minutos hace

Ironing issues could have been been done as NWBO owned company as well and hit could have been taken there as well.
Not sure you are even getting the very basics of what my post said .
Will assist setting up with whose money ?

NWBO

bigrun 21 minutos hace

When is it going pink current? Thx.

VGTL

Chromosome 23 minutos hace

And the more extreme case of that is called channel stuffing. The CEO of ArthroCare got 20 year prison sentence for inflating revenue by making sweet deals with distributors to take product in exchange for discounts and ability to sell back later.
Obviously that is not the case here but was t

AMRN

blownaccount9 23 minutos hace

Threw back a few to celebrate. Today isn't about share appreciation, but the fact that the 3 most critical people to getting this show on the F'ing road are all ready and in place. I don't care what shares traded at today, tomorrow, or next week. The odds of getting a favorable release I'd say are a

FNMA

XMaster2023 23 minutos hace

First of all, manufacturing is where the risk is. If someone screws up, Advent will take the hit.
Second, we need Advent to iron out the manufacturing issues. They are primarily dedicated to NWBO.
Third, there will be other manufacturers in other locations, but I’m almost positive

NWBO

FastEddie18585 23 minutos hace

"In a series of tweets Thursday evening, newly confirmed FHFA Director Bill Pulte made it clear that pulling Fannie Mae and Freddie Mac out of conservatorship is his top priority and wrote: “big announcements coming soon.”"

FNMA

955 23 minutos hace

Tariffs Will Make US Strong

https://investorshub.advfn.com/uimage/uploads/2025/3/14/njbosCrashingEconomy7.jpg

EmpressMonk25 24 minutos hace

You think I'm over here with diarrhea and ulcers because the price went down? 😂

The question remains... will I get my 0.0002s? By the way, the only way I get my 0.0002s is when we see 0.0001s and not even instantly will the 0.0001s let me buy the 0.0002s!

Patie

HMBL

nowwhat2 25 minutos hace

re : Ripple, etc.

https://investorshub.advfn.com/uimage/uploads/2025/3/14/xkcyuSPY_~_13_ZOOM_DEATH_CROSS_FIGURE_Q.jpg

https://investorshub.advfn.com/uimage/uploads/2025/3/14/juodxspy_~_12_5y_TT_OVAL_200.jpg

XRPUSD

thecrusher2011 25 minutos hace

Jean Carroll along with Democrat donors lobbied the state of New York to get the law passed that allowed her to bring the suit even though it was far past the statute of limitations even for civil suits.

Jean Carroll helped pass the law, they admitted it on CNN. This whole thing was

Datos

Noticias

Herramientas

Mercados

Descubrir

Hot Features

Follow Feed

Flujo de Opciones

Monitor

Centessa Pharmaceuticals Plc (0ACX)

Discusiones en tiempo real e ideas comerciales: opere con confianza con nuestra poderosa plataforma.

Estadísticas y detalles clave

Acerca de Centessa Pharmaceuticals Plc

0ACX Últimas noticias

Centessa Pharmaceuticals Reports Financial Results for the Third Quarter of 2024 and Provides Business Update

Centessa Pharmaceuticals Announces Pricing of Upsized $225,000,000 Public Offering of American Depositary Shares

Centessa Pharmaceuticals Announces $150,000,000 Proposed Public Offering of American Depositary Shares

Centessa Announces Positive Interim Phase 1 Clinical Data with its Novel Orexin Receptor 2 (OX2R) Agonist, ORX750, in Acutely Sleep-Deprived Healthy Volunteers

Centessa Pharmaceuticals Announces Late-Breaking Poster Presentation of Non-Human Primate Data for ORX142, a Novel Orexin Receptor 2 (OX2R) Agonist, at the 27th Congress of the European Sleep Research Society (Sleep Europe 2024)

Centessa Pharmaceuticals Reports Financial Results and Business Highlights for the Second Quarter of 2024

Centessa Pharmaceuticals Reports Financial Results for the Third Quarter of 2024 and Provides Business Update

Centessa Pharmaceuticals Announces Pricing of Upsized $225,000,000 Public Offering of American Depositary Shares

Centessa Pharmaceuticals Announces $150,000,000 Proposed Public Offering of American Depositary Shares

Centessa Announces Positive Interim Phase 1 Clinical Data with its Novel Orexin Receptor 2 (OX2R) Agonist, ORX750, in Acutely Sleep-Deprived Healthy Volunteers

Centessa Pharmaceuticals Announces Late-Breaking Poster Presentation of Non-Human Primate Data for ORX142, a Novel Orexin Receptor 2 (OX2R) Agonist, at the 27th Congress of the European Sleep Research Society (Sleep Europe 2024)

Centessa Pharmaceuticals Reports Financial Results and Business Highlights for the Second Quarter of 2024

0ACX - Preguntas Frecuentes

Movimientos

Discusión

Su Consulta Reciente

Empresa

Negocios

Popular

Obtener la aplicación

Período †	Variación(Ptos)	Variación %	Apertura	Precio Máximo	Precio Mínimo	Avg. Vol. diario	Precio Promedio Ponderado
1	0	0	0	0	0	0	0	DE
4	0	0	0	0	0	0	0	DE
12	0	0	0	0	0	0	0	DE
26	0	0	0	0	0	0	0	DE
52	0	0	0	0	0	0	0	DE
156	0	0	0	0	0	0	0	DE
260	0	0	0	0	0	0	0	DE

Período †	Variación(Ptos)	Variación %	Apertura	Precio Máximo	Precio Mínimo	Avg. Vol. diario	Precio Promedio Ponderado
1	0	0	0	0	0	0	0	DE
4	0	0	0	0	0	0	0	DE
12	0	0	0	0	0	0	0	DE
26	0	0	0	0	0	0	0	DE
52	0	0	0	0	0	0	0	DE
156	0	0	0	0	0	0	0	DE
260	0	0	0	0	0	0	0	DE

Tendencias Ahora

Listas Principales

Datos

Noticias

Herramientas

Mercados

Descubrir

Hot Features

Follow Feed

Flujo de Opciones

Monitor

Centessa Pharmaceuticals Plc (0ACX) Cotización

Centessa Pharmaceuticals Plc (0ACX)

Discusiones en tiempo real e ideas comerciales: opere con confianza con nuestra poderosa plataforma.

Estadísticas y detalles clave

Acerca de Centessa Pharmaceuticals Plc

0ACX Últimas noticias

Centessa Pharmaceuticals Reports Financial Results for the Third Quarter of 2024 and Provides Business Update

Centessa Pharmaceuticals Announces Pricing of Upsized $225,000,000 Public Offering of American Depositary Shares

Centessa Pharmaceuticals Announces $150,000,000 Proposed Public Offering of American Depositary Shares

Centessa Announces Positive Interim Phase 1 Clinical Data with its Novel Orexin Receptor 2 (OX2R) Agonist, ORX750, in Acutely Sleep-Deprived Healthy Volunteers

Centessa Pharmaceuticals Announces Late-Breaking Poster Presentation of Non-Human Primate Data for ORX142, a Novel Orexin Receptor 2 (OX2R) Agonist, at the 27th Congress of the European Sleep Research Society (Sleep Europe 2024)

Centessa Pharmaceuticals Reports Financial Results and Business Highlights for the Second Quarter of 2024

Centessa Pharmaceuticals Reports Financial Results for the Third Quarter of 2024 and Provides Business Update

Centessa Pharmaceuticals Announces Pricing of Upsized $225,000,000 Public Offering of American Depositary Shares

Centessa Pharmaceuticals Announces $150,000,000 Proposed Public Offering of American Depositary Shares

Centessa Announces Positive Interim Phase 1 Clinical Data with its Novel Orexin Receptor 2 (OX2R) Agonist, ORX750, in Acutely Sleep-Deprived Healthy Volunteers

Centessa Pharmaceuticals Announces Late-Breaking Poster Presentation of Non-Human Primate Data for ORX142, a Novel Orexin Receptor 2 (OX2R) Agonist, at the 27th Congress of the European Sleep Research Society (Sleep Europe 2024)

Centessa Pharmaceuticals Reports Financial Results and Business Highlights for the Second Quarter of 2024

0ACX - Preguntas Frecuentes

Movimientos

Discusión

Su Consulta Reciente

Empresa

Negocios

Popular

Obtener la aplicación

Quitar anuncios

Período †	Variación(Ptos)	Variación %	Apertura	Precio Máximo	Precio Mínimo	Avg. Vol. diario	Precio Promedio Ponderado
1	0	0	0	0	0	0	0	DE
4	0	0	0	0	0	0	0	DE
12	0	0	0	0	0	0	0	DE
26	0	0	0	0	0	0	0	DE
52	0	0	0	0	0	0	0	DE
156	0	0	0	0	0	0	0	DE
260	0	0	0	0	0	0	0	DE